Lilly's Zepbound Boosts Taltz Response in Psoriasis Study
Lilly reports Zepbound (tirzepatide) enhanced Taltz (ixekizumab) efficacy in a psoriasis study, a signal for combination therapy in metabolic-psoriatic disease.
Section
Therapeutics & Pipeline
Drug approvals, trial readouts and treatment guidelines.
Palvella Puts U.S. DSAP Population at 154,986 in New Posters
Palvella Therapeutics posters estimate 154,986 U.S. patients with disseminated superficial actinic porokeratosis, sharpening the…
Palvella Brings Clinical and Claims Data to Dermatology Conference Stage
Palvella Therapeutics presented clinical and claims data at a dermatology conference, pairing trial results with real-world analy…
Palvella to Present Three Posters on Microcystic Lymphatic Malformations and DSAP
Palvella Therapeutics will present three posters with new data on microcystic lymphatic malformations and DSAP at Fall Clinical D…
Pemphigus Vulgaris Therapy Pipeline Expands Beyond Rituximab
A new EMJ review details how pemphigus vulgaris treatment is broadening beyond rituximab, with pipeline candidates targeting fast…
Lilly Reports Taltz-Zepbound Combo Beats Taltz Alone in Psoriasis Study
Eli Lilly says a psoriasis study found Taltz plus Zepbound outperformed Taltz monotherapy; full efficacy and safety data are stil…
GLP-1 Combination Therapy Signals New Benefits in Psoriasis
NewsNation reports GLP-1 combination therapy may unlock new benefits for psoriasis patients, extending the metabolic-skin overlap…
Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension
Phase 3 extension data show denifanstat, an oral fatty acid synthase inhibitor, sustained acne improvement through 52 weeks — the…
Denifanstat Shows Deeper Acne Results Through 52 Weeks
Denifanstat, an investigational oral acne therapy, showed deeper results through 52 weeks of treatment in data presented at the 2…
FDA Approves Priteliver for Refractory Herpes Infections
The US FDA has approved pritelivir for refractory herpes infections, giving dermatologists a new option for patients who fail sta…